Stock Events

Stock Events

Brainstorm Cell Therapeutics 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q1 2026
Next
-0.31
-0.26
-0.21
-0.16
Expected EPS
-0.25433
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-8.98MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GHDN.MU. It's not an investment recommendation.
Apple
8
AAPL
NVIDIA
8
NVDA
Microsoft
7
MSFT
AMD
7
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Stem
STEM
Mkt Cap62.34M
StemCells, Inc. focuses on cell-based therapeutics, directly competing in the regenerative medicine space similar to BCLI's focus on neurological conditions.
Mesoblast
MESO
Mkt Cap2B
Mesoblast Limited develops mesenchymal lineage adult stem cell therapies, targeting conditions that overlap with BCLI's therapeutic areas.
Biolife Solutions
BLFS
Mkt Cap1.38B
BioLife Solutions, Inc. provides bioproduction tools and services, including cell and gene therapy solutions, supporting the same market as BCLI.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics AG focuses on gene editing, a cutting-edge area of biotech that competes with stem cell therapy approaches in treating genetic disorders.
Vericel
VCEL
Mkt Cap2.4B
Vericel Corporation specializes in autologous cell therapies for the treatment of patients with serious diseases, including neurological conditions.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics, Inc. develops genomic therapies, offering an alternative to traditional stem cell therapies in treating genetic disorders.
Novartis
NVS
Mkt Cap293.94B
Novartis AG, through its advanced therapy platforms, competes in the broader market of innovative treatments for neurological and other diseases.

About

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Show more...
CEO
Mr. Chaim Lebovits
Employees
29
Country
United States
ISIN
US10501E2019

Listings

MU
DE
GHDN.MU
STU
DE
GHD.STU
MU
DE
GHD.MU
OTC Link
US
BCLI

0 Comments

Share your thoughts

FAQ

What is Brainstorm Cell Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Brainstorm Cell Therapeutics stocks are traded under the ticker GHDN.MU.
When is the next Brainstorm Cell Therapeutics earnings date?▼
Brainstorm Cell Therapeutics is going to release the next earnings report on August 17, 2026.
What were Brainstorm Cell Therapeutics earnings last quarter?▼
GHDN.MU earnings for the last quarter are -0.16 EUR per share, whereas the estimation was -0.31 EUR resulting in a +47.22% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Brainstorm Cell Therapeutics revenue for the last year?▼
Brainstorm Cell Therapeutics revenue for the last year amounts to 0 EUR.
What is Brainstorm Cell Therapeutics net income for the last year?▼
GHDN.MU net income for the last year is -8.98M EUR.
How many employees does Brainstorm Cell Therapeutics have?▼
As of July 22, 2026, the company has 29 employees.
In which sector is Brainstorm Cell Therapeutics located?▼
Brainstorm Cell Therapeutics operates in the Health & Wellness sector.
When did Brainstorm Cell Therapeutics complete a stock split?▼
The last stock split for Brainstorm Cell Therapeutics was on October 01, 2024 with a ratio of 1:15.
Where is Brainstorm Cell Therapeutics headquartered?▼
Brainstorm Cell Therapeutics is headquartered in New York, United States.